Principal Financial Group’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $35.5M | Sell |
645,341
-20,185
| -3% | -$826K | 0.02% | 667 |
|
|
2026
Q1 | $22.1M | Sell |
665,526
-182,261
| -21% | -$5.43M | 0.01% | 862 |
|
|
2025
Q4 | $25.3M | Buy |
847,787
+63,615
| +8% | +$2.08M | 0.01% | 756 |
|
|
2025
Q3 | $28.3M | Sell |
784,172
-12,502
| -2% | -$412K | 0.01% | 675 |
|
|
2025
Q2 | $28.7M | Sell |
796,674
-44,337
| -5% | -$1.65M | 0.02% | 660 |
|
|
2025
Q1 | $33.2M | Buy |
841,011
+10,827
| +1% | +$364K | 0.02% | 571 |
|
|
2024
Q4 | $25M | Buy |
830,184
+57,996
| +8% | +$1.66M | 0.01% | 729 |
|
|
2024
Q3 | $18.1M | Buy |
772,188
+725,371
| +1,549% | +$15.8M | 0.01% | 905 |
|
|
2024
Q2 | $833K | Buy |
46,817
+11,443
| +32% | +$183K | ﹤0.01% | 1877 |
|
|
2024
Q1 | $538K | Buy |
35,374
+1,322
| +4% | +$21.1K | ﹤0.01% | 1971 |
|
|
2023
Q4 | $582K | Buy |
34,052
+412
| +1% | +$4.79K | ﹤0.01% | 1932 |
|
|
2023
Q3 | $281K | Sell |
33,640
-18,439
| -35% | -$257K | ﹤0.01% | 2074 |
|
|
2023
Q2 | $1.29M | Sell |
52,079
-11,897
| -19% | -$307K | ﹤0.01% | 1812 |
|
|
2023
Q1 | $962K | Buy |
63,976
+24,346
| +61% | +$370K | ﹤0.01% | 1858 |
|
|
2022
Q4 | $469K | Buy |
39,630
+3,722
| +10% | +$27K | ﹤0.01% | 1993 |
|
|
2022
Q3 | $213K | Sell |
35,908
-785
| -2% | -$5.15K | ﹤0.01% | 2189 |
|
|
2022
Q2 | $156K | Sell |
36,693
-3,204
| -8% | -$20K | ﹤0.01% | 2336 |
|
|
2022
Q1 | $380K | Buy |
39,897
+776
| +2% | +$8.98K | ﹤0.01% | 2180 |
|
|
2021
Q4 | $743K | Sell |
39,121
-16,163
| -29% | -$420K | ﹤0.01% | 2042 |
|
|
2021
Q3 | $1.84M | Buy |
55,284
+1,860
| +3% | +$57.5K | ﹤0.01% | 1885 |
|
|
2021
Q2 | $2.07M | Buy |
53,424
+877
| +2% | +$34.4K | ﹤0.01% | 1898 |
|
|
2021
Q1 | $2.53M | Buy |
52,547
+395
| +0.8% | +$19K | ﹤0.01% | 1817 |
|
|
2020
Q4 | $2.71M | Buy |
52,152
+15,830
| +44% | +$535K | ﹤0.01% | 1738 |
|
|
2020
Q3 | $972K | Sell |
36,322
-709
| -2% | -$16.3K | ﹤0.01% | 1876 |
|
|
2020
Q2 | $722K | Buy |
37,031
+11,840
| +47% | +$191K | ﹤0.01% | 1888 |
|
|
2020
Q1 | $247K | Buy |
25,191
+790
| +3% | +$9.98K | ﹤0.01% | 2013 |
|
|
2019
Q4 | $271K | Buy |
24,401
+12,760
| +110% | +$97K | ﹤0.01% | 2074 |
|
|
2019
Q3 | $65K | Buy |
+11,641
| New | +$81.2K | ﹤0.01% | 2203 |
|
|
2018
Q4 | – | Sell |
-11,063
| Closed | -$62K | – | 2306 |
|
|
2018
Q3 | $62K | Buy |
+11,063
| New | +$126K | ﹤0.01% | 2257 |
|
Other funds holding TGTX
SCM
CAM
Principal Financial Group's TGTX Position: Q2 2026 in Review
Principal Financial Group reduced its TG Therapeutics (TGTX) stake by 3% in Q2 2026, selling an estimated $826K and leaving 645,341 shares worth $35.5M. The position accounts for 0.02% of the portfolio, ranked #667.
Principal Financial Group first reported a position in TGTX in Q3 2018 and has held it in 29 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.
- Principal Financial Group held 645,341 shares of TG Therapeutics worth $35.5M as of Q2 2026.
- Principal Financial Group sold 20,185 TG Therapeutics shares in Q2 2026, an estimated $826K.
- TG Therapeutics made up 0.02% of Principal Financial Group's portfolio in Q2 2026, its #667 holding.
- Principal Financial Group first reported a position in TG Therapeutics in Q3 2018 and has held it in 29 quarters since.
- 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.
Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.